The global immunomodulators market is expected to reach USD 233.7
billion by 2025, according to this new study. The market is anticipated
to be predominantly driven by high R&D investments employed by the
prominent companies, resulting into the large-scale production of new
and therapeutically advanced drugs. This is believed to widen the influx
of drugs at an unprecedented rate into the immunomodulators market hence
providing highly efficacious treatment alternatives for numerous
autoimmune and inflammatory diseases.

In addition, increasing drugs resistance is predicted to be responsible
for boosting the clinical urgency to develop potentially new generation
immunomodulators with targeted therapy mechanisms. The aforementioned
factors cumulatively are expected to present significant growth
opportunities over the forecast period.

Furthermore, burgeoning presence of the key players is expected to
promote the awareness levels pertaining to benefits of immunomodulators
amongst the patients as well as the physicians. This is further expected
to widen the immunomodulators industry growth potential during the
forecast period.

In addition, increasing adoption of monoclonal antibodies for a wide
range of indications, such as, multiple sclerosis, Crohn's disease,
rheumatoid arthritis, and Non-Hodgkin's Lymphoma, which is expected to
boost immunomodulators industry over the forecast period. The consistent
number of product approvals of highly significant monoclonal antibodies
in autoimmune diseases is predicted to be responsible for widening the
scope of growth.

For instance, in March 2015, Novartis AG entered into research
collaboration with Aduro Biotech. This was carried out to enhance its
next generation cancer immunotherapy product pipeline